Jan. 19, 2021
Oxford BioTherapeutics Designates Second Bispecific Antibody Program Leveraging WuXi Biologics’ WuXiBody® Platform
WuXi Biologics
Offering End-to-End Solutions
Services
& Solutions
A leading global open-access biologics technology platform offering end-to-end solutions to empower organizations to discover, develop and manufacture biologics from concept to commercial manufacturing.
Technologies
Technology platforms that span the entire drug discovery to manufacturing spectrum.
Bioconjugation
Greatly simplifies bioconjugate drug development by providing CMC development.
Mammalian
Unparalleled capacities and expertise for the discovery, development and cGMP manufacture of biologics from concept to commercialization.
Testing
Providing extensive expertise and high-quality biosafety testing under EMA, ISO (CNAS) and CMA certified laboratories.
Microbial
E. coli and yeast based expression systems, process development and cGMP manufacturing platform
Quality
World-class quality systems approved by the U.S. FDA, EMA and NMPA.
Viral
Viral vector based vaccine and therapeutic virus development and cGMP manufacturing platform.
Locations
Total estimated capacity for biopharmaceutical production in China, Ireland, the U.S., Germany and Singapore to exceed 280,000 liters by 2023.
United States
Ireland
Germany
Singapore
China
Notice:
You are leaving WuXi Biologics Website, after which our Privacy Notice will not apply. Please keep it in mind the protection of your privacy. Are you willing to proceed?